Amid shortages, maker says restrictions on Wegovy will continue into 2024

As demand for the wildly popular weight-loss drug Wegovy continues to climb, drug maker Novo Nordisk said Thursday that it will continue restrictions on starter doses of the medication into 2024. The new plan extends by months existing restrictions and means patients who are not already taking the medication will have to wait to start.

Leave A Comment

Your email address will not be published. Required fields are marked *